NEWSLETTER

By clicking submit, you agree to share your email address with TFN to receive marketing, updates, and other emails from the site owner. Use the unsubscribe link in the emails to opt out at any time.

Jay-Z’s MarcyPen and Gwyneth Paltrow’s Kinship back Hone Health’s $228M longevity round

Hone Health
Image credits: Home Health
  • Hone Health raised $228 million, compromising of $28 million equity. The other $200 million was from General Catalyst’s Customer Value Fund.
  • MarcyPen, the fund run by Jay-Z and Jay Brown, led the round. Gwyneth Paltrow’s Kinship Ventures also took part.
  • Hone made over $100 million in recurring revenue last year and has seen approximately 200,000 patients.

Saad Alam at 35 was feeling worn out, had some memory lapses, was putting on weight and was depressed. His doctor told him, “South Asian men age a little bit earlier so just get used to it”.

That experience was the genesis of Hone Health which just raised $228 million in funding with just $28 million in equity.

Alam told Tech Funding News it took him about a year to find doctors who would diagnose his hormone imbalance. “Today the consumer has almost infinite options for preventative health, what they want is the highest level of insight into their metrics so they can make more informed health decisions,” said Alam.

“Hone brings that level of insight by combining comprehensive diagnostic testing, physician-led care and AI-powered insights,” he added.

Why only $28M is equity?

The raise breaks down as $28 million in equity (Series A) and $200 million in growth funding from General Catalyst’s Customer Value Fund, also known as CVF.

The same fund provided Function Health with $450 million in July and has also invested in Europe’s Finom.

Alam says Hone has circa 450 staff, including doctors, and is only operating in the US at the moment. In January 2025, the company reported 55,000 patients treated.

This round follows Hone’s $33 million Series A which was announced in January 2025. MarcyPen led that round, taking the total equity funding to $65 million.

“People have never had more data on their own bodies and never less guidance on what to do with it. Hone closes that gap by bringing serious diagnostics together with physicians who stay with you over the long term rather than just seeing you for a few appointments. That long-term relationship is the foundation of our Health OS thesis and we’re very excited about the potential for Hone,” said Omar Hatteea, investment manager at Pentland Ventures.

Hone Black, the company’s concierge membership, is launching publicly after a year in stealth. It offers testing for over 1,600 markers, as well as peptides, exosome, and stem cell therapies. The FDA has warned that exosome products are unapproved, and legal experts say peptide compounding is still under review.

Celebrity investors and Kinship Ventures are joining this round

MarcyPen was formed in Dec 2024 as a merger of Jay-Z’s Marcy Venture Partners and Pendulum Holdings’ investment arm.

“Saad and the team at Hone are proven business builders who are focused on making it easier for people to live better, healthier lives,”said Brown, co-founder and managing partner at MarcyPen.

The other investors include Nick, Joe and Kevin Jonas, Kelly Rowland, actor Marcello Hernandez, NFL player Braxton Berrios, Knicks owner Quentin Dolan, Kyle Samani and Halle Tecco. Hanwha, Gannet Capital, humbition and Comma Capital are also on board.

Kinship Ventures’ co-founder Gwyneth Paltrow added, “When I started goop, wellness was a very niche thing. It’s now one of the biggest categories in the world and the next step is to actually bring real health and wellness to the masses rather than just a select few. Saad has built Hone to do that precisely, with real science and at scale.”

Competitors, clinical trials, and regulatory issues

Alam says Hone is frequently compared to Hims & Hers, whereas Hone is about “true longevity care to reduce your biological age.” Rival Neko Health raised $700m in July and Hone has added Prenuvo whole body MRI.

Alam makes it clear that Hone’s mission is much more than just about delivering care: “Hone isn’t just a virtual care company, it’s actually a company that does clinical trials and ultimately commercialises the medicines.”

The funding will go towards Longevity OS, new areas, such as metabolic care and PCOS, expanded diagnostics, clinical trials and peptides.

Total
0
Shares
Related Posts
Total
0
Share
tfn-logo-2-220x220-removebg-preview

Get daily funding news briefings in the tech world delivered right to your inbox.

Enter Your Email
join our newsletter. thank you
TFN Banner